www.managedhealthcareexecutive.com Open in urlscan Pro
76.76.21.22  Public Scan

Form analysis
2 forms found in the DOM

<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>

<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>

Text Content

CONTINUE TO SITE

OR WAIT null SECS

Advertisement


 * 
 * 
 * 
 * 

Search
Resource Centers
View MoreAsthmaAtrial FibrillationBiosimilarsBlood
CancerCovid-19DermatologyDigital HealthEye CareHemophiliaHIVLiver
DiseaseMultiple SclerosisPost-Acute CarePrescription Digital
TherapeuticsRespiratory ConditionsSleep DisordersSubstance Use DisorderType II
InflammationUlcerative Colitis
AsthmaAtrial FibrillationBiosimilarsBlood CancerCovid-19DermatologyDigital
HealthEye CareHemophiliaHIVLiver DiseaseMultiple SclerosisPost-Acute
CarePrescription Digital TherapeuticsRespiratory ConditionsSleep
DisordersSubstance Use DisorderType II InflammationUlcerative Colitis
Spotlight
AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving
Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives:
Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven
ConditionsPBMI National ConferenceUnbranded Biologics: An Overview
AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving
Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives:
Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven
ConditionsPBMI National ConferenceUnbranded Biologics: An Overview
Business
View MoreBusiness StrategyChronic DiseaseConsumersDrug CostsDrug
PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals &
ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice
ManagementReimbursementTechnology
Business StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth
ManagementHealth/Disease StrategyHospitals & ProvidersIndustry
AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology
News
Media
Expert Interviews
K-Cast
Medical World News
Podcasts
Population Health Perspectives
Expert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives
ConferencesPartners
Publications
MHE Publication
Supplements And Featured Publications
MHE PublicationSupplements And Featured Publications
Events
Virtual Events
Virtual Events
CME/CE
Resources
PBM Leaders
Sponsored
Sponsored Content
Surveys
PBM LeadersSponsoredSponsored ContentSurveys
Subscribe
eNewsletter
Print Subscription
eNewsletterPrint Subscription
 * Advertise
 * Editorial
 * Contact Us
 * Terms and Conditions
 * Privacy
 * Do Not Sell My Personal Informations

 * 

© 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Search
Advertisement


Resource CentersSee All >
 * Asthma
 * Atrial Fibrillation
 * Biosimilars
 * Blood Cancer
 * Covid-19
 * Dermatology
 * Digital Health
 * Eye Care
 * Hemophilia
 * HIV
 * Liver Disease
 * Multiple Sclerosis
 * Post-Acute Care
 * Prescription Digital Therapeutics
 * Respiratory Conditions
 * Sleep Disorders
 * Substance Use Disorder
 * Type II Inflammation
 * Ulcerative Colitis

Spotlight
 * AMCP Annual
 * Asembia’s 2022 Specialty Pharmacy Summit
 * AMCP Nexus
 * Examining Evolving Treatment Paradigms in the Hemophilia B Space
 * Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining
   Care in Behavior-Driven Conditions
 * PBMI National Conference
 * Unbranded Biologics: An Overview

BusinessSee All >
 * Business Strategy
 * Chronic Disease
 * Consumers
 * Drug Costs
 * Drug Pipeline
 * Formulary
 * Health Management
 * Health/Disease Strategy
 * Hospitals & Providers
 * Industry Analysis
 * Pharmacy
 * Politics and Policy
 * Practice Management
 * Reimbursement
 * Technology

Advertisement


 * Advertise
 * Editorial
 * Contact Us
 * Terms and Conditions
 * Privacy
 * Do Not Sell My Personal Informations
 * 

 * 

© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.


RISK OF COVID-19 MAY INCREASE FOR VACCINATED DEPENDING ON TIME OF LAST
CONTRACTION



January 10th 2023

Researchers at Cleveland Clinic evaluated whether a bivalent COVID-19 vaccine
protects against both strains of the virus - the original virus strain and a
component of the omicron variant.




ENGINEERED PROBIOTICS TARGET PROINFLAMMATORY MOLECULES AND IMPROVE ULCERATIVE
COLITIS SYMPTOMS



January 9th 2023

Stomach acid interferes with the effectiveness of probiotics taken as pills.
Researchers are bioengineering probiotics in hopes of getting around that
problem.




AI MAY BE ABLE TO HELP DIAGNOSE OSTEOARTHRITIS EARLY



January 9th 2023

Artificial intelligence can locate tibial spiking in x-ray images, which many
believe to be an early sign of knee osteoarthritis.




HEART RATE, MOVEMENT MAY USED TO PREDICT VO2 MAX



January 9th 2023

Researchers investigated whether it might be possible to use AI and machine
learning to develop a model that could use data from everyday activity (rather
than workouts) to accurately predict VO2max.




CUSTOM HEALTH, L.A. CARE TEAM UP ON ADHERENCE PILOT



January 9th 2023

Custom is one of the growing number of companies focusing on adherence. It
changed its name from Pack4U last year.

Advertisement


Advertisement



ENSURE YOU PARTNER WITH PROBLEM SOLVERS, NOT PROBLEM FINDERS

January 08, 2023

ByAndrew Perlstein


What’s more valuable than the ability to identify problems within your business
plan or strategy? The ability to find solutions to those problems before they
arise.



FDA UPDATES FOR THE WEEK OF JAN. 3, 2023

January 07, 2023

ByDenise Myshko


The FDA ends the week with the approval of the Alzheimer’s medication lecanemab.
Two other approvals include: Olpruva for urea cycle disorders and Wegovy for
weight loss in teens. The agency has also accepted several applications,
including Genentech’s second bispecific antibody, glofitamab, for blood cancer,
UCB’s second application for generalized myasthenia gravis, and a therapy RSV
prevention in infants. Two companies have submitted applications: Celltrion for
a new formulation of infliximab and Orasis for blurry vision treatment.



FDA APPROVES NEW ALZHEIMER'S DRUG, LEQEMBI. CAN IT ESCAPE ADUHELM'S FATE?

January 07, 2023




Leqembi's starting price is almost half of what Aduhelm's was and the
FDA-approved label narrows use to people with early disease. But Medicare
coverage restrictions may still apply and there is concern about a side effect
called ARIA (amyloid related imaging abnormalities).



BIPARTISAN AGREEMENT ON HEALTH POLICY IS POSSIBLE

January 06, 2023




Experts say Democrats and Republicans could work together on telehealth, mental
health and physician payment issues in 2023.



FOR ALS TREATMENTS, THREE GENES ARE TARGETS

January 05, 2023




Dozens of gene mutations associated with amyotrophic lateral sclerosis have been
identified. Drug developers have homed in on a trio of genes.


Next >>
Advertisement


Advertisement


Advertisement


x







×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and use personal data (e.g., your IP address). If you
consent, the cookies, device identifiers, or other information can be stored or
accessed on your device for the purposes described below. You can click "Allow
All" or "Decline All" or click Settings above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners if you wish to provide or deny consent for specific partners, review
the purposes each partner believes they have a legitimate interest for, and
object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences